1. 1864PGenotyping of circulating tumor DNA in biliary tract cancer reveals diagnostic and prognostic information. (23rd October 2018) Authors: Ettrich, T J; Schwerdel, D; Dolnik, A; Beuter, F; Blätte, T; Schmidt, S A; Stanescu-Siegmund, N; Steinacker, J; Marienfeld, R; Kleger, A; Bullinger, L; Seufferlein, T; Berger, A W Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1874PA composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma. (23rd October 2018) Authors: Berger, A W; Ettrich, T J; Schwerdel, D; Reinacher-Schick, A; Algül, H; König, A-O; Gallmeier, E; Wille, K; Daum, S; Geissler, M; Tannapfel, A; Uhl, W; Seufferlein, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 427PPhase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma. (23rd October 2018) Authors: Moek, K L; Fiedler, W M; von Einem, J C; Verheul, H M; Seufferlein, T; de Groot, D J; Heinemann, V; Kebenko, M; Menke-van der Houven van Oordt, C W; Ettrich, T J; Rasmussen, E; Bogner, P; Sable, B; Stienen, S; de Vries, E G E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 453PD1st-line mFOLFOXIRI + panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: A randomized phase II VOLFI trial of the AIO (KRK-0109). (23rd October 2018) Authors: Geissler, M; Klingler, T; Riera Knorrenschild, J; Tannapfel, A; Greeve, J; Seufferlein, T; Kanzler, S; Held, S; Heinemann, V; Reinacher-Schick, A; Martens, U M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 474PA novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial. (23rd October 2018) Authors: Seufferlein, T; Lausser, L; Stein, A; Prager, G; Kasper, S; Niedermeier, M; Müller, L; Kubicka, S; König, A-O; Büchner-Steudel, P; Wille, K; Perkhofer, L; Hann, A; Berger, A W; Arnold, D; Kestler, H; Ettrich, T J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 564PTRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: Final results from the randomized phase II trial of the AIO. (23rd October 2018) Authors: Ettrich, T J; Berger, A W; Decker, T; Hofheinz, R D; Heinemann, V; Hoffmann, T; Hebart, H F; Herrmann, T; Hannig, C-V; Büchner-Steudel, P; Bartholomäus, H; Güthle, M; Perkhofer, L; Seufferlein, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Issue 10 (7th June 2009) Authors: Schneiderhan, W; Scheler, M; Holzmann, K-H; Marx, M; Gschwend, J E; Bucholz, M; Gress, T M; Seufferlein, T; Adler, G; Oswald, F Journal: Gut Issue: Volume 58:Issue 10(2009) Page Start: 1391 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. O-024mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109). (20th June 2018) Authors: Geissler, M; Klingler, T; Riera-Knorrenschield, J; Tannapfel, A; Seufferlein, T; Held, S; Florschütz, A; Kanzler, S; Heinemann, V; Reinacher-Schick, A; Martens, U Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P-008Treatment decisions in adolescents and young adults with gastric cancer in North Estonia Medical Centre from 2007-2016. (20th June 2018) Authors: Lõhmus, M; Lepik, K; Kütt, T; Seufferlein, T; Oselin, K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P-098TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). (2nd July 2019) Authors: Hammel, P; Feliu, J; Parner, V; Berardi, R; Van Cutsem, E; Greil, R; Wasan, H; Metges, J; Nygren, P; Osterlund, P; Seufferlein, T; Creemers, G; Biswas-Baldwin, N; Youssoufian, H; Gupta, A; Salesse, S; Dion, H; El-Hariry, I; Hidalgo, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗